Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 25, 2025 03:00 ET | Source: ITM Isotope Technologies Munich SE

ITM Announces Analyses from Phase 3 COMPETE Data Showing Higher Objective Response Rates with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus Across Subgroups of Patients with GEP-NETs at NANETS 2025 Annual Symposium

Austin, Texas, October 25, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, announced analyses data from its Phase 3 COMPETE trial in patients with Grade...
October 18, 2025 05:15 ET | Source: ITM Isotope Technologies Munich SE

ITM Announces Phase 3 COMPETE Data Demonstrating a Statistically Significant Higher Objective Response Rate with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus in Patients with Gastroenteropancreatic Neuroendocrine Tumors at ESMO 2025

Study data also showed prolonged progression-free survival with 177Lu-edotreotide compared to everolimus across patient subgroups Berlin, Germany, October 18, 2025 – ITM Isotope Technologies Munich...
October 17, 2025 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM to Announce Phase 3 COMPETE Trial Post Hoc Subgroup Analyses and Host Satellite Symposium at NANETS 2025

Garching / Munich, Germany, October 17, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that post hoc subgroup analyses data from its...
October 13, 2025 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM Appoints Annette Breunig as Chief People Officer

Global HR leader to drive ITM’s long-term human resources strategy, support organizational development and corporate growth Garching / Munich, Germany, October 13, 2025 – ITM Isotope Technologies...
October 08, 2025 06:00 ET | Source: ITM Isotope Technologies Munich SE

ITM Presents Dosimetry Data from Phase 3 COMPETE Trial Supporting Favorable Efficacy and Safety Profile with n.c.a. 177Lu-edotreotide (ITM-11) in Patients with Gastroenteropancreatic Neuroendocrine Tumors at EANM 2025 Annual Congress

Study showed targeted tumor uptake with low healthy organ exposure in broad cohort of 207 patientsSupports therapeutic potential of ITM’s proprietary targeted radiotherapeutic agentAbstract receives...
October 01, 2025 05:00 ET | Source: NUCLIDIUM AG

NUCLIDIUM Receives Notice of Allowance for Composition-of-Matter Patent Covering FAP inhibitor-based Radiodiagnostics and Therapeutics in the United States

Basel, Switzerland / Munich, Germany, October 01, 2025 – NUCLIDIUM AG, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, today announced that it...
September 24, 2025 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM and TerThera Sign Supply Agreement for Medical Radioisotope Terbium-161

Garching / Munich, Germany, and Breda, the Netherlands, September 24, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and TerThera BV, a leading...
September 16, 2025 05:07 ET | Source: ITM Isotope Technologies Munich SE

ITM to Present COMPETE Dosimetry Data and Host Satellite Symposium at EANM 2025

Garching / Munich, Germany, September 16, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will unveil dosimetry data from its...
September 16, 2025 05:00 ET | Source: NUCLIDIUM AG

NUCLIDIUM to Present Clinical Data from Phase I/II Study for Copper-based PET-Diagnostic in Neuroendocrine Tumors at EANM 2025

Basel, Switzerland / Munich, Germany, September 16, 2025 – NUCLIDIUM AG, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, today announced that...
August 08, 2025 06:35 ET | Source: Y-mAbs Therapeutics, Inc.

Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments

Reported Total Revenues of $19.5 million for the second quarter of 2025, exceeding the high end of the Company’s guidance range of between $17 million and $19 millionSERB Pharmaceuticals to acquire...